Last 12 months
Inside the activity.
0 purchase rows · 74 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 7 |
| Jan 2026 | 0 | 6 |
| Feb 2026 | 0 | 6 |
| Mar 2026 | 0 | 9 |
| Apr 2026 | 0 | 2 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 7 |
| Jul 2026 | 0 | 5 |
| Aug 2026 | 0 | 9 |
| Sep 2026 | 0 | 6 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 10, 2026 Filed Feb 11, 2026 22:17 UTC |
Widman FredrikVP Corporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 567 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001897970-26-000002 · edgardoc.xml · derivative · entry 4 Widman Fredrik · CIK 0001897970 · VP Corporate Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 567 Underlying: Common Stock · 567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F3 · derivative.expiration_date: Constitute restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock upon vesting. 25% of the RSUs shall vest on each anniversary of February 10, 2023, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:17 UTC |
Widman FredrikVP Corporate Controller
|
Tax withholdingCommon Stock | 302 | $492.84 | $148,837.68 |
DisclosureSEC source: 0001897970-26-000002 · edgardoc.xml · nonDerivative · entry 2 Widman Fredrik · CIK 0001897970 · VP Corporate Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 793 F1 · kind: RSUs vest 25% per year over a four year period, commencing on each anniversary of February 10, 2023. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account. Read SEC document |
| February 10, 2026 Filed Feb 11, 2026 22:17 UTC |
Widman FredrikVP Corporate Controller
|
Exercise / conversionCommon Stock | 567 | $0.00 | $0.00 |
DisclosureSEC source: 0001897970-26-000002 · edgardoc.xml · nonDerivative · entry 1 Widman Fredrik · CIK 0001897970 · VP Corporate Controller 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: RSUs vest 25% per year over a four year period, commencing on each anniversary of February 10, 2023. RSUs convert into common stock on the vest date on a one-for-one basis. 25% of the shares have been released and a portion of the shares were held back to cover the statutory tax withholding requirements. The net shares were deposited into the holders account. Read SEC document |
| January 29, 2026 Filed Jan 31, 2026 02:45 UTC |
Leonard Keith RDirector
|
OtherCommon Stock | 369 | $0.00 | $0.00 |
DisclosureSEC source: 0001416180-26-000002 · edgardoc.xml · nonDerivative · entry 1 Leonard Keith R · CIK 0001416180 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370 F1 · kind: Transfer of shares pursuant to divorce decree. Read SEC document |
| January 29, 2026 Filed Jan 31, 2026 02:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 126 | $0.00 Strike: $208.90 | $0.00 |
DisclosureSEC source: 0001632901-26-000004 · edgardoc.xml · derivative · entry 4 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125 Underlying: Common Stock · 126 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter. Read SEC document |
| January 29, 2026 Filed Jan 31, 2026 02:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
SaleCommon Stock | 126 | $520.02 | $65,522.52 |
DisclosureSEC source: 0001632901-26-000004 · edgardoc.xml · nonDerivative · entry 2 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| January 29, 2026 Filed Jan 31, 2026 02:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 126 | $208.90 | $26,321.40 |
DisclosureSEC source: 0001632901-26-000004 · edgardoc.xml · nonDerivative · entry 1 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:12 UTC |
GUTHART GARY SDirector
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 17,556 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001280628-26-000004 · edgardoc.xml · derivative · entry 2 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,556 Underlying: Common Stock · 17,556 shares Expires not disclosed F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:12 UTC |
GUTHART GARY SDirector
|
GrantPerformance Stock Units - 2-26-2024 · Derivative | 8,267 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001280628-26-000004 · edgardoc.xml · derivative · entry 1 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,267 Underlying: Common Stock · 8,267 shares Expires not disclosed F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:03 UTC |
Samath JamieEVP & CFO & Enterprise Technol
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 7,182 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001330269-26-000002 · edgardoc.xml · derivative · entry 2 Samath Jamie · CIK 0001330269 · EVP & CFO & Enterprise Technol 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,182 Underlying: Common Stock · 7,182 shares Expires not disclosed F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:03 UTC |
Samath JamieEVP & CFO & Enterprise Technol
|
GrantPerformance Stock Units - 2-26-2024 · Derivative | 3,180 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001330269-26-000002 · edgardoc.xml · derivative · entry 1 Samath Jamie · CIK 0001330269 · EVP & CFO & Enterprise Technol 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,180 Underlying: Common Stock · 3,180 shares Expires not disclosed F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:20 UTC |
Rosa David J.Director · Chief Executive Officer (CEO)
|
GrantPerformance Stock Units - 6-12-2023 · Derivative | 6,034 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001519593-26-000002 · edgardoc.xml · derivative · entry 3 Rosa David J. · CIK 0001519593 · Director · Chief Executive Officer (CEO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,034 Underlying: Common Stock · 6,034 shares Expires not disclosed F3 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on June 12, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28. 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F3 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on June 12, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28. 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:20 UTC |
Rosa David J.Director · Chief Executive Officer (CEO)
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 9,575 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001519593-26-000002 · edgardoc.xml · derivative · entry 2 Rosa David J. · CIK 0001519593 · Director · Chief Executive Officer (CEO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,575 Underlying: Common Stock · 9,575 shares Expires not disclosed F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:20 UTC |
Rosa David J.Director · Chief Executive Officer (CEO)
|
GrantPerformance Stock Units - 2-26-2024 · Derivative | 6,360 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001519593-26-000002 · edgardoc.xml · derivative · entry 1 Rosa David J. · CIK 0001519593 · Director · Chief Executive Officer (CEO) 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,360 Underlying: Common Stock · 6,360 shares Expires not disclosed F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:24 UTC |
LOEB GARYEVP & Chief Legal and Complian
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 2,098 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001561733-26-000002 · edgardoc.xml · derivative · entry 2 LOEB GARY · CIK 0001561733 · EVP & Chief Legal and Complian 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,098 Underlying: Common Stock · 2,098 shares Expires not disclosed F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:24 UTC |
LOEB GARYEVP & Chief Legal and Complian
|
GrantPerformance Stock Units - 2-26-2024 · Derivative | 2,543 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001561733-26-000002 · edgardoc.xml · derivative · entry 1 LOEB GARY · CIK 0001561733 · EVP & Chief Legal and Complian 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,543 Underlying: Common Stock · 2,543 shares Expires not disclosed F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 5,585 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001632901-26-000004 · edgardoc.xml · derivative · entry 5 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,585 Underlying: Common Stock · 5,585 shares Expires not disclosed F3 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F3 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:08 UTC |
Charlton Henry LEVP & Chief Commercial and Mkt
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 7,182 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001897642-26-000002 · edgardoc.xml · derivative · entry 2 Charlton Henry L · CIK 0001897642 · EVP & Chief Commercial and Mkt 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,182 Underlying: Common Stock · 7,182 shares Expires not disclosed F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:08 UTC |
Charlton Henry LEVP & Chief Commercial and Mkt
|
GrantPerformance Stock Units - 2-26-2024 · Derivative | 2,861 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001897642-26-000002 · edgardoc.xml · derivative · entry 1 Charlton Henry L · CIK 0001897642 · EVP & Chief Commercial and Mkt 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,861 Underlying: Common Stock · 2,861 shares Expires not disclosed F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:28 UTC |
Brosius MarkSVP & Chief Mfg and Supply Cha
|
GrantPerformance Stock Units - 2-28-2023 · Derivative | 5,585 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002010300-26-000003 · edgardoc.xml · derivative · entry 2 Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,585 Underlying: Common Stock · 5,585 shares Expires not disclosed F2 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F2 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 28, 2023 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 28, 2026, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 28, 2026 Filed Jan 31, 2026 02:28 UTC |
Brosius MarkSVP & Chief Mfg and Supply Cha
|
GrantPerformance Stock Units - 2-26-2024 · Derivative | 2,702 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002010300-26-000003 · edgardoc.xml · derivative · entry 1 Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,702 Underlying: Common Stock · 2,702 shares Expires not disclosed F1 · derivative.exercise_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents performance stock units ("PSUs") initially granted to the Reporting Person on February 26, 2024 subject to achievement of certain performance metrics. The performance criteria for the PSUs reported herein have been achieved, as determined by the Compensation Committee of the Issuer. The PSUs reported herein vest on February 26, 2027, the third anniversary of the grant date, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:20 UTC |
GUTHART GARY SDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,500 | $0.00 Strike: $174.26 | $0.00 |
DisclosureSEC source: 0001280628-26-000002 · edgardoc.xml · derivative · entry 6 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,500 shares Expires 2028-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F5 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:20 UTC |
GUTHART GARY SDirector
|
SaleCommon Stock | 1,400 | $531.52 | $744,129.12 |
DisclosureSEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 4 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust FBO Son Disclosed balance after: 15,720 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 360 shares sold at $530.98 to $531.86; 240 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:20 UTC |
GUTHART GARY SDirector
|
SaleCommon Stock | 1,400 | $531.53 | $744,139.90 |
DisclosureSEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 3 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: Plan reported Ownership: Indirect · Trust FBO Daughter Disclosed balance after: 15,720 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 298 shares sold at $530.98 to $531.87; 302 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:20 UTC |
GUTHART GARY SDirector
|
SaleCommon Stock | 24,500 | $530.10 | $12,987,403.45 |
DisclosureSEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 2 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,694 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $525.51 to $534.00 as follows: 2,500 shares sold at $525.51 to $525.71; 280 shares sold at $526.94 to $527.41; 2,252 shares sold at $528.23 to $529.18; 9,860 shares sold at $529.27 to $530.27; 3,475 shares sold at $530.29 to $531.22; 1,589 shares sold at $531.37 to $532.24; 3,704 shares sold at $532.53 to $533.41; and 840 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:20 UTC |
GUTHART GARY SDirector
|
Exercise / conversionCommon Stock | 25,500 | $174.26 | $4,443,545.85 |
DisclosureSEC source: 0001280628-26-000002 · edgardoc.xml · nonDerivative · entry 1 GUTHART GARY S · CIK 0001280628 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:34 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 105 | $0.00 Strike: $229.39 | $0.00 |
DisclosureSEC source: 0001632901-26-000002 · edgardoc.xml · derivative · entry 7 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,362 Underlying: Common Stock · 105 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F3 · derivative.exercise_date: 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:34 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125 | $0.00 Strike: $208.90 | $0.00 |
DisclosureSEC source: 0001632901-26-000002 · edgardoc.xml · derivative · entry 6 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 251 Underlying: Common Stock · 125 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:34 UTC |
Curet MyriamEVP & Chief Medical Officer
|
SaleCommon Stock | 125 | $532.61 | $66,576.25 |
DisclosureSEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 4 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:34 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 125 | $208.90 | $26,112.50 |
DisclosureSEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 3 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:34 UTC |
Curet MyriamEVP & Chief Medical Officer
|
SaleCommon Stock | 105 | $532.61 | $55,924.05 |
DisclosureSEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 2 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| January 27, 2026 Filed Jan 28, 2026 21:34 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 105 | $229.39 | $24,085.95 |
DisclosureSEC source: 0001632901-26-000002 · edgardoc.xml · nonDerivative · entry 1 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| December 15, 2025 Filed Dec 15, 2025 23:52 UTC |
Brosius MarkSVP & Chief Mfg and Supply Cha
|
SaleCommon Stock | 464 | $548.49 | $254,499.36 |
DisclosureSEC source: 0002010300-25-000004 · edgardoc.xml · nonDerivative · entry 3 Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 443 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. Read SEC document |
| December 15, 2025 Filed Dec 17, 2025 23:59 UTC |
Brosius MarkSee Remarks
|
SaleCommon Stock | 464 | $548.49 | $254,499.36 |
DisclosureSEC source: 0001610717-25-000419 · form4.xml · nonDerivative · entry 1 Brosius Mark · CIK 0002010300 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. Read SEC document |
| December 12, 2025 Filed Dec 15, 2025 23:52 UTC |
Brosius MarkSVP & Chief Mfg and Supply Cha
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $79.64 | $0.00 |
DisclosureSEC source: 0002010300-25-000004 · edgardoc.xml · derivative · entry 4 Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2027-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter. Read SEC document |
| December 12, 2025 Filed Dec 15, 2025 23:52 UTC |
Brosius MarkSVP & Chief Mfg and Supply Cha
|
SaleCommon Stock | 4,500 | $547.36 | $2,463,120.00 |
DisclosureSEC source: 0002010300-25-000004 · edgardoc.xml · nonDerivative · entry 2 Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 907 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. Read SEC document |
| December 12, 2025 Filed Dec 15, 2025 23:52 UTC |
Brosius MarkSVP & Chief Mfg and Supply Cha
|
Exercise / conversionCommon Stock | 4,500 | $79.64 | $358,370.10 |
DisclosureSEC source: 0002010300-25-000004 · edgardoc.xml · nonDerivative · entry 1 Brosius Mark · CIK 0002010300 · SVP & Chief Mfg and Supply Cha 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,407 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. Read SEC document |
| December 12, 2025 Filed Dec 17, 2025 23:43 UTC Amendment |
Brosius MarkSee Remarks
|
SaleCommon Stock | 312 | $547.36 | $170,776.32 |
DisclosureSEC source: 0001610717-25-000418 · form4.xml · nonDerivative · entry 1 Brosius Mark · CIK 0002010300 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 595 F2 · date: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. F2 · shares: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. F2 · price: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. F2 · balance_after: The third transaction line in Table I of the Form 4 filed by the Reporting Person on 12/15/2025 incorrectly reported the transaction details. The transaction line as reported herein has been restated to correct the errors in the original Form 4. Except as otherwise noted in this footnote, all other information disclosed in the Reporting Person's original Form 4 was accurately reported. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:23 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 104 | $0.00 Strike: $229.39 | $0.00 |
DisclosureSEC source: 0001632901-25-000010 · edgardoc.xml · derivative · entry 4 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,467 Underlying: Common Stock · 104 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F2 · derivative.exercise_date: 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:23 UTC |
Curet MyriamEVP & Chief Medical Officer
|
SaleCommon Stock | 104 | $559.90 | $58,229.60 |
DisclosureSEC source: 0001632901-25-000010 · edgardoc.xml · nonDerivative · entry 2 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| December 10, 2025 Filed Dec 10, 2025 23:23 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 104 | $229.39 | $23,856.56 |
DisclosureSEC source: 0001632901-25-000010 · edgardoc.xml · nonDerivative · entry 1 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 17:50 UTC |
GUTHART GARY SDirector · Executive Chair of the Board o
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 25,500 | $0.00 Strike: $139.52 | $0.00 |
DisclosureSEC source: 0001280628-25-000006 · edgardoc.xml · derivative · entry 6 GUTHART GARY S · CIK 0001280628 · Director · Executive Chair of the Board o 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,500 shares Expires 2028-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F3 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 17:50 UTC |
GUTHART GARY SDirector · Executive Chair of the Board o
|
SaleCommon Stock | 22,806 | $570.89 | $13,019,721.90 |
DisclosureSEC source: 0001280628-25-000006 · edgardoc.xml · nonDerivative · entry 2 GUTHART GARY S · CIK 0001280628 · Director · Executive Chair of the Board o 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,694 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $568.62 to $573.54 as follows: 5,550 shares sold at $568.62 to $569.62; 6,304 shares sold at $569.64 to $570.63; 2,285 shares sold at $570.66 to $571.61; 5,528 shares sold at $571.70 to $572.70; 3,139 shares sold at $572.72 to $573.54. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 17:50 UTC |
GUTHART GARY SDirector · Executive Chair of the Board o
|
Exercise / conversionCommon Stock | 25,500 | $139.52 | $3,557,760.00 |
DisclosureSEC source: 0001280628-25-000006 · edgardoc.xml · nonDerivative · entry 1 GUTHART GARY S · CIK 0001280628 · Director · Executive Chair of the Board o 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 125 | $0.00 Strike: $208.90 | $0.00 |
DisclosureSEC source: 0001632901-25-000008 · edgardoc.xml · derivative · entry 4 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 376 Underlying: Common Stock · 125 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
SaleCommon Stock | 125 | $568.99 | $71,123.75 |
DisclosureSEC source: 0001632901-25-000008 · edgardoc.xml · nonDerivative · entry 2 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:16 UTC |
Curet MyriamEVP & Chief Medical Officer
|
Exercise / conversionCommon Stock | 125 | $208.90 | $26,112.50 |
DisclosureSEC source: 0001632901-25-000008 · edgardoc.xml · nonDerivative · entry 1 Curet Myriam · CIK 0001632901 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 18:46 UTC |
BARRATT CRAIG HDirector
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 750 | $0.00 Strike: $71.32 | $0.00 |
DisclosureSEC source: 0001277620-25-000008 · edgardoc.xml · derivative · entry 4 BARRATT CRAIG H · CIK 0001277620 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires 2026-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. F2 · derivative.exercise_date: Non-statutory stock option granted pursuant to the Non-Employee Directors' Stock Option Plan. Option shall vest 100% one year after the date of grant or at the next Shareholders Meeting, whichever should take place first, provided that vesting will cease on termination of the Directors service to the Company. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 18:46 UTC |
BARRATT CRAIG HDirector
|
SaleCommon Stock | 750 | $580.00 | $435,000.00 |
DisclosureSEC source: 0001277620-25-000008 · edgardoc.xml · nonDerivative · entry 2 BARRATT CRAIG H · CIK 0001277620 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. Read SEC document |
| November 12, 2025 Filed Nov 13, 2025 18:46 UTC |
BARRATT CRAIG HDirector
|
Exercise / conversionCommon Stock | 750 | $71.32 | $53,492.48 |
DisclosureSEC source: 0001277620-25-000008 · edgardoc.xml · nonDerivative · entry 1 BARRATT CRAIG H · CIK 0001277620 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.